176 results on '"Shell, R."'
Search Results
2. Mycobacterium Avium Complex Associated Mediastinal Lymphadenitis and Endobronchial Lesion in a Previously Healthy Infant
3. FP.23 Bulbar function for patients with spinal muscular atrophy type 1 following onasemnogene abeparvovec
4. P.134a Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update
5. Intelligent Robots for Flexible Packaging
6. DMD - TREATMENT
7. S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1
8. DECREASED RIGHT VENTRICULAR FUNCTION IN HEALTHY PEDIATRIC CYSTIC FIBROSIS PATIENTS VS. NON-CYSTIC FIBROSIS PATIENTS: 340
9. DMD – THERAPY
10. SMA – THERAPY
11. OUTCOME MEASURES
12. Thérapie génique (TG) dans l’amyotrophie spinale de type 1 (SMA1) : suivi à long terme (SLT) de l’essai clinique de phase 1 évaluant l’onasemnogène abeparvovec
13. Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1: Pulmonary and Ventilatory Findings from the Pivotal Phase 3 US Study (STR1VE)
14. Effectiveness of Airway Clearance in Duchenne Muscular Dystrophy
15. Seeing Past the Smoke: Eosinophilic Pneumonia with Lymphadenopathy in Association with Vaping and THC Use
16. S61 Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): preliminary pulmonary and ventilatory findings from the phase 3 study (STR1VE)
17. Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial
18. P.365Clinical outcomes in patients with spinal muscular atrophy type 1, 2 or 3 after 1 year of nusinersen therapy
19. P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial
20. AVXS-101 Gene Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
21. AVXS-101 Phase 1 Gene-Replacement Therapy (GRT) Clinical Trial in Spinal Muscular Atrophy Type 1 (SMA1): 24-Month Event-Free Survival and Achievement of Developmental Milestones
22. DMD - TREATMENT: EP.139 Phase 1/2a trial of SRP-9001 in patients with Duchenne muscular dystrophy: 3-year safety and functional outcomes
23. SMA THERAPIES I
24. SMA THERAPIES I
25. SMA THERAPIES I
26. PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY
27. INTRODUCTION TO S.E. HUDSON'S ”SLAVES”
28. Nusinersen versus sham control in infantile-onset spinal muscular atrophy
29. AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: decreased need of ventilatory and nutritional support at End-of-Study
30. AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: end-of-Study event free survival and achievement of developmental milestones
31. AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: patients treated early with the proposed therapeutic dose were able to sit unassisted at a younger age
32. Ab initio studies of the vibrational spectra and structure of phosphorus halides. I. Selection of basis functions and the spectra of PCl3.
33. Addressing discrepancies in care with the certified Duchenne care center program
34. P.374 - AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: patients treated early with the proposed therapeutic dose were able to sit unassisted at a younger age
35. P.373 - AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: decreased need of ventilatory and nutritional support at End-of-Study
36. P.372 - AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: end-of-Study event free survival and achievement of developmental milestones
37. Morphometric Analysis of Dinosaur Tracks from Southwest Arkansas
38. G.P.44 - Addressing discrepancies in care with the certified Duchenne care center program
39. Your list's 'worth': adding it up
40. Theory of planned behaviour predictors of intention to use condoms among Xhosa adolescents in South Africa
41. Theoretical basis for general lifting equations based on mechanical work performed during manual lifting
42. The concept of work compatibility: An integrated design criterion for improving workplace human performance in manufacturing systems
43. An adaptive control model for assessment of work-related musculoskeletal hazards and risks
44. Back to the future
45. Look before you leap into a home-based business
46. Use of visual perception in estimating static postural stresses: magnitudes and sources of errors
47. Theoretical basis for general mixed object handling equations based on mechanical work required.
48. Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor.
49. Psychosocial factors and musculoskeletal disorders in the construction industry: a systematic review.
50. Workplace bullying: a systematic review of risk factors and outcomes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.